Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 17INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Genitourinary 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 1Keratosis, Actinic 1Carcinoma, Transitional Cell 1Carcinoma, Basal Cell 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × 1-phenyl-3,3-dimethyltriazene × Clear all
NCT00472043 2024-08-06

PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma

Galderma R&D

Phase 3 Completed
66 enrolled 15 charts
Dermatologic

Carcinoma, Basal Cell

NCT01966120 2023-07-28

Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)

Biofrontera Bioscience GmbH

Phase 3 Completed
87 enrolled 21 charts
Dermatologic

Keratosis, Actinic

NCT03053635 2018-08-20

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

TheralaseĀ® Technologies Inc.

Phase 1 Completed
6 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚔